Anavex Life Sciences (AVXL) EBITDA (2016 - 2025)
Anavex Life Sciences recorded quarterly EBITDA of -$5.7 million in Q4 2025, up 47.78% quarter-over-quarter from -$10.8 million in Q3 2025, and up 58.34% year-over-year from -$3.6 million in Q4 2024.
Anavex Life Sciences' EBITDA history runs 10 years deep, the most recent figure standing at -$5.7 million for Q4 2025.
- In Q4 2025, EBITDA rose 58.34% year-over-year to -$5.7 million; the TTM figure through Dec 2025 stood at -$43.5 million (up 21.08% YoY), while the FY2025 annual figure was -$51.4 million, up 2.78% from the prior year.
- EBITDA came in at -$5.7 million for Q4 2025 at Anavex Life Sciences, up from -$10.8 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$5.7 million in Q4 2025 to a low of -$15.4 million in Q4 2022.
- A 5-year average of -$12.3 million and a median of -$12.6 million in 2024 frame the typical range for EBITDA.
- Across the five-year window, EBITDA plunged 94.34% in 2021 and soared 58.34% in 2025, its largest moves.
- Anavex Life Sciences' EBITDA stood at -$11.7 million in 2021, then plunged by 31.22% to -$15.4 million in 2022, then advanced by 26.04% to -$11.4 million in 2023, then declined by 19.46% to -$13.6 million in 2024, then jumped by 58.34% to -$5.7 million in 2025.
- According to Business Quant data, EBITDA over the past three periods registered -$5.7 million, -$10.8 million, and -$14.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | -5.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.66 Mn |
| Sep 30, 2025 | -10.84 Mn |
| Jun 30, 2025 | -14.46 Mn |
| Mar 31, 2025 | -12.51 Mn |
| Dec 31, 2024 | -13.59 Mn |
| Sep 30, 2024 | -14.27 Mn |
| Jun 30, 2024 | -14.60 Mn |
| Mar 31, 2024 | -12.62 Mn |
| Dec 31, 2023 | -11.38 Mn |
| Sep 30, 2023 | -12.66 Mn |
| Jun 30, 2023 | -13.53 Mn |
| Mar 31, 2023 | -14.19 Mn |
| Dec 31, 2022 | -15.38 Mn |
| Sep 30, 2022 | -15.28 Mn |
| Jun 30, 2022 | -12.46 Mn |
| Mar 31, 2022 | -11.52 Mn |
| Dec 31, 2021 | -11.72 Mn |
| Sep 30, 2021 | -11.58 Mn |
| Jun 30, 2021 | -10.14 Mn |
| Mar 31, 2021 | -8.13 Mn |
| Dec 31, 2020 | -7.80 Mn |
| Sep 30, 2020 | -5.96 Mn |
| Jun 30, 2020 | -6.48 Mn |
| Mar 31, 2020 | -7.24 Mn |
| Dec 31, 2019 | -6.58 Mn |
| Sep 30, 2019 | -5.60 Mn |
| Jun 30, 2019 | -6.50 Mn |
| Mar 31, 2019 | -7.20 Mn |
| Dec 31, 2018 | -6.91 Mn |
| Sep 30, 2018 | -5.56 Mn |
| Jun 30, 2018 | -2.85 Mn |
| Mar 31, 2018 | -4.72 Mn |
| Dec 31, 2017 | -4.05 Mn |
| Sep 30, 2017 | -5.15 Mn |
| Jun 30, 2017 | -3.60 Mn |
| Mar 31, 2017 | -1.54 Mn |
| Dec 31, 2016 | -3.12 Mn |
| Sep 30, 2016 | -6.51 Mn |
| Jun 30, 2016 | -2.23 Mn |